Margaret L Ong1, Robert S Venick2, Stephen B Shew3, James C Y Dunn3, Laurie Reyen2, Tristan Grogan4, Kara L Calkins5. 1. Department of Pediatrics, David Geffen School of Medicine UCLA, Mattel Children's Hospital at UCLA, Los Angeles, California, USA. 2. Division of Gastroenterology, Department of Pediatrics, David Geffen School of Medicine UCLA, Mattel Children's Hospital at UCLA, Los Angeles, California, USA. 3. Division of Pediatric Surgery, Department of Surgery, Stanford University, Palo Alto, California, USA. 4. Department of Medicine, David Geffen School of Medicine UCLA, Los Angeles, California, USA. 5. Division of Neonatology and Developmental Biology, Department of Pediatrics, David Geffen School of Medicine UCLA, Mattel Children's Hospital at UCLA, Los Angeles, California, USA.
Abstract
BACKGROUND: Intravenous fish oil (FO) treats pediatric intestinal failure-associated liver disease (IFALD). There are concerns that a lipid emulsion composed of ω-3 fatty acids will cause an essential fatty acid deficiency (EFAD). This study's objective was to quantify the risk for abnormal fatty acid concentrations in children treated with FO. METHODS: Inclusion criteria for this prospective study were children with intestinal failure. Intravenous soybean oil (SO) was replaced with FO for no longer than 6 months. Serum fatty acids were analyzed using linear and logistic models, and compared with age-based norms to determine the percentage of subjects with low and high concentrations. RESULTS: Subjects (n = 17) started receiving FO at a median of 3.6 months (interquartile range 2.4-9.6 months). Over time, α-linolenic, linoleic, arachidonic, and Mead acid decreased, whereas docosahexaenoic and eicosapentaenoic acid increased (P < 0.001 for all). Triene-tetraene ratios remained unchanged (P = 1). Although subjects were 1.8 times more likely to develop a low linoleic acid while receiving FO vs SO (95% CI: 1.4-2.3, P < 0.01), there was not a significant risk for low arachidonic acid. Subjects were 1.6 times more likely to develop high docosahexaenoic acid while receiving FO vs SO; however, this was not significant (95% CI: 0.9-2.6, P = 0.08). CONCLUSION: In this cohort of parenteral nutrition-dependent children, switching from SO to FO led to a decrease in essential fatty acid concentrations, but an EFAD was not evident. Low and high levels of fatty acids developed. Further investigation is needed to clarify if this is clinically significant.
BACKGROUND: Intravenous fish oil (FO) treats pediatric intestinal failure-associated liver disease (IFALD). There are concerns that a lipid emulsion composed of ω-3 fatty acids will cause an essential fatty acid deficiency (EFAD). This study's objective was to quantify the risk for abnormal fatty acid concentrations in children treated with FO. METHODS: Inclusion criteria for this prospective study were children with intestinal failure. Intravenous soybean oil (SO) was replaced with FO for no longer than 6 months. Serum fatty acids were analyzed using linear and logistic models, and compared with age-based norms to determine the percentage of subjects with low and high concentrations. RESULTS: Subjects (n = 17) started receiving FO at a median of 3.6 months (interquartile range 2.4-9.6 months). Over time, α-linolenic, linoleic, arachidonic, and Mead acid decreased, whereas docosahexaenoic and eicosapentaenoic acid increased (P < 0.001 for all). Triene-tetraene ratios remained unchanged (P = 1). Although subjects were 1.8 times more likely to develop a low linoleic acid while receiving FO vs SO (95% CI: 1.4-2.3, P < 0.01), there was not a significant risk for low arachidonic acid. Subjects were 1.6 times more likely to develop high docosahexaenoic acid while receiving FO vs SO; however, this was not significant (95% CI: 0.9-2.6, P = 0.08). CONCLUSION: In this cohort of parenteral nutrition-dependent children, switching from SO to FO led to a decrease in essential fatty acid concentrations, but an EFAD was not evident. Low and high levels of fatty acids developed. Further investigation is needed to clarify if this is clinically significant.
Authors: Mary Petrea Cober; Ghassan Killu; Allison Brattain; Kathleen B Welch; Shaun M Kunisaki; Daniel H Teitelbaum Journal: J Pediatr Date: 2011-10-06 Impact factor: 4.406
Authors: Camilia R Martin; Deborah A Dasilva; Joanne E Cluette-Brown; Clementina Dimonda; Ashley Hamill; Abdul Q Bhutta; Emmanuel Coronel; Michael Wilschanski; Alisa J Stephens; David F Driscoll; Bruce R Bistrian; James H Ware; Munir M Zaman; Steven D Freedman Journal: J Pediatr Date: 2011-06-12 Impact factor: 4.406
Authors: Hau D Le; Vincent E de Meijer; Elizabeth M Robinson; David Zurakowski; Alexis K Potemkin; Danielle A Arsenault; Erica M Fallon; Alpin Malkan; Bruce R Bistrian; Kathleen M Gura; Mark Puder Journal: Am J Clin Nutr Date: 2011-07-20 Impact factor: 7.045
Authors: Hau D Le; Erica M Fallon; Brian T Kalish; Vincent E de Meijer; Jonathan A Meisel; Kathleen M Gura; Vania Nose; Amy H Pan; Bruce R Bistrian; Mark Puder Journal: Metabolism Date: 2012-11-12 Impact factor: 8.694
Authors: Catherine J Klein; Thomas G Havranek; Mary E Revenis; Zahra Hassanali; Louis M Scavo Journal: Nutr Clin Pract Date: 2013-02 Impact factor: 3.080
Authors: Vincent E de Meijer; Hau D Le; Jonathan A Meisel; Kathleen M Gura; Mark Puder Journal: J Pediatr Gastroenterol Nutr Date: 2010-02 Impact factor: 2.839